EAU Position Statement on Screening for Prost...( ARNHEM The Netherlands April 16 /...),Health

ARNHEM, The Netherlands, April 16 /PRNewswire/ -- The European Association of Urology (EAU) has taken into consideration the recent scientific information on randomised screening studies on prostate cancer (Schröder et al, NEJM 2009). Based on the results of the European Randomised Study for Screening of Prostate Cancer (ERSPC), the EAU has formulated a position statement regarding prostate cancer screening in Europe, and the subsequent actions to be taken by health professionals and health authorities.

In summary, the ERSPC reports on a relative prostate cancer mortality reduction of at least 20% by PSA-based population screening in 162,000 asymptomatic men aged 55-69 years. For every prostate cancer death prevented, 1410 men have to undergo screening, while 48 are needed to be treated in excess of the control group population to save one prostate cancer death. Results of the PLCO (Prostate, Lung, Colon and Ovary) US randomized study of screening were also published in the same issue of the NEJM (Andriole et al, NEJM 2009) and to date show no significant effect of screening on mortality from the disease, but suffered from a significant level of contamination in the control arm. The study continues.

The EAU adopts the conclusions of the ERSPC study and recognizes the benefit of screening in terms of mortality reduction, as well as the adverse effects of overdiagnosis and overtreatment of prostate cancers which could be quantified for the first time in the setting of a randomized screening study. Further publication of relevant data is awaited from the ERSPC group in due course to inform the debate.

For the interest men's health in Europe and elsewhere, the EAU formulates the following statements:

    - Prostate cancer is a major health problem, and one of the
    main causes of male cancer deaths. However, current published data are
    insufficient to recommend the adoption o
'/>"/>
SOURCE  European Association of Urology
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 
Related medicine technology :

1. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
2. Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients
3. AAOMS Updates BRONJ Position Paper
4. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
5. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
6. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
9. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
10. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
11. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling